EE447 Cost Implications of Adverse Event Profiles in Second Generation Androgen Receptor Inhibitor (SGARI) Treatments for Non-Metastatic Castration Resistant Prostate Cancer (NMCRPC)
Abstract
Authors
J Chou E Bell I Brewer S Appukkuttan J Partridge SX Kong R Maclean